Pharmaceutical Science III - Anticancer, Antimitotic & Platinum, Monoclonal & Tyrosine Kinase Inhibitor agents (Dr. Hilliard)

0.0(0)
Studied by 1 person
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/48

encourage image

There's no tags or description

Looks like no tags are added yet.

49 Terms

1
New cards

what is the role of mitotic spindles

partitioning of DNA into 2 daughter cells

2
New cards

antimitotic: vincristine, vinblastine, vinorelbine

interferes with microtubule function by binding to tubulin

IV, fatal with other routes

M phase

3
New cards

vincristine

TX:
ALL
Hodgkins and non Hodgkins

S/E:
- dose limiting neurotoxicity with peripheral neuropathy
- alopecia
- mild myelosuppression

4
New cards

what is the R-CHOP therapy for non-Hodgkins lymphoma

Rituximab
Cyclophosphamide
doxorubicin Hcl
Vincristine
Prednisone

5
New cards

what is the ABVD therapy for Hodgkins lymphoma

Doxorubicin
Bleomycin
Vincristine
Dacarbazine
Prednisone

6
New cards

vinblastine

TX:
NH and H lymphoma

S/E: myelosuppression and neurotoxicity

7
New cards

what combo is used for testicular cancer

vinblastine
bleomycin
cisplatin

8
New cards

vinorelbine

TX
advanced non small cell

S/E: granulocytopenia

9
New cards

Anti microtubules

G2/M phase

promote polymerization and prevent disassembly that leads to accumulation and cell death

10
New cards

Anti microtubules: paclitaxel & docetaxel

S/E: neutropenia, leukopenia

11
New cards

patients treated with paclitaxel should be premedicated with

dexamethasone
diphenhydramine

12
New cards

topoisomerase inhibitors I

irinotecan
topotecan

S phase topo I

IV

13
New cards

platinum

cisplatin
carboplatin
oxaliplatin

14
New cards

platinum Moa

cross link DNA and interfere with DNA synthesis and cell replication like alkylating agents

G1 and S phase

15
New cards

what tumors are cisplatin targeting

solid

16
New cards

cisplatin

dose limiting nephrotoxicity
neurotoxicity
ototoxicity
infusion rxn

17
New cards

carboplatin

pts should be vigorously hydrated

neuro and ototoxicity

18
New cards

oxaliplatin

tx: colorectal cancer

neuro and liver toxicity
infusion rxn

19
New cards

oncogenes are developed from normal ___

proto-oncogenes

20
New cards

oncogenes turn healthy cells into ___

cancer cells

21
New cards

proto-oncogenes

important in normal cellular function

22
New cards

genetic alterations in proto-oncogenes

pt mutation
chromosomal rearrangement
gene amplification

23
New cards

oncogenes examples

EGFR:
HER2, 3, 4

24
New cards

monoclonal antibodies

targeted therapy

created from B lymphocytes from immunized mice infused with immoral b lymphocyte tumor cells

25
New cards

trastuzumab

moa: overexpression of HER2 and blocks downstream signaling pathway

breast
gastric

S/E: pulmonary toxicity, HF

26
New cards

rituximab

moa: antagonist against CD20 antigen on malignant B lymphocytes in NH lymphoma

R-CHOP

S/E: hypotension, bronchospasm, angioedema

infuse slowly

admin with APAP, Benadryl, and corticosteroids

27
New cards

what was the first monoclonal used for cancer TX

rituximab

28
New cards

bevacizumab

moa: antiangiogenesis; stops VEGF

TX: colorectal cancer

used with 5-FU

S/E: HTN, GI, proteinuria, bleeding

29
New cards

cetuximab & panitumumab

moa: KRAS on EGFR

rash is positive TX sign

IV

30
New cards

most serious S/E for bleomycin

pulmonary toxicity

31
New cards

FOLFIRINOX TX for GI tumors

Leucovorin
5-FU
Irinotecan
Oxaliplatin

32
New cards

which of the following drugs is not apart of FLOFIRINOX combo

a/ sunitinib
b/ leucovorin
c/ irinotecan
d/ 5-FU
e/ oxaliplatin

sunitinib

33
New cards

a 32 yr old male suffering from a cold started taking several different OTC cold/flu medications to relieve symptoms. she was later admitted to the hospital with elevated levels of N-acteyl-p- benzoquinone. what toxicity is of potential serious importance?

hepatotoxicity

34
New cards

a patient is preparing for pre-op analgesia and the anesthesiologist needs an adjuvant anesthesia that has rapid onset and short duration and 100x more potent than morphine. what is the agent

fentanyl

35
New cards

treatment for acute and chronic lymphocytic leukemia, NH lymphoma, breast, ovarian cancer and produced nephrotoxic and urotoxic metabolite acrolein. what is the agent

cyclophosphamide

36
New cards

a patient diagnosed with pancreatic cancer was administered agent IV. he begins to develop myelosuppression and hepatic toxicity. what drug is he taking

gemcitabine

37
New cards

a physician prescribed an immune checkpoint inhibitor to treat metastatic melanoma and the patient developed autoimmune toxicity. what drug is he taking

a. ipilimumab
b/ olaparib
c. venetoclax
d/ thalidomide
e/ lapatinib

a. ipilimumab

38
New cards

a patient was prescribed proteasome inhibitor and developed thrombocytopenia, fatigue and peripheral neuropathy. what drug is responsible

a/ bortezomib
b/ rituximab
c/ ofatmumab
d/ sorafenib
e/ pazopanib

a/ bortezomib

39
New cards

which of the following is not a major problem with drug resistance in cancer chemo

a/ activation of cancer drugs
b/ increased DNA repair
c/ changes in targeted enzymes
d/ decreased drug accumultation
e/ decreased activation of prodrugs

a/ activation of cancer drugs

40
New cards

this drug is a pyrimidine analog antimetabolite agent from the cytotoxic drug class that substitutes for the normal uracil in RNA so inhibits protein synthesis and the cells can't proliferate

a/ 5-FU
b/ cyclophosphamide
c/ 6- mercaptopurine
d/ premetrexate
e/ methotrexate

a/ 5-FU

41
New cards

a patient with testicular and H lymphoma cancer presented to the ER experiencing pulmonary toxicity and mucocutaneous rxn. what drug is respsonsible

a/ bleomycin
b/ doxorubicin
c/ cyclophosphamide
d/ fulvestrant
e/ anastrazole

a/ bleomycin

42
New cards

Bill developed thrombocytopenia, peripheral neuropathy, and fatigue. during relapse therapy for multiple melanoma. what drug is repsonsible

a/ bortezomib
b/ imatinib
c/ carmustine
d/ panitumumab
e/ gemtuzumab

a/ bortezomib

43
New cards

this patient developed advance NSCLC that is resistant to other EGFR kinase inhibitors. which kinase inhibitor is best suited for treatment

a/ osimertinib
b/ certuximab
c/ lapatinib
d/ neratinib
e/ trastuzumab

a/ osimertinib

44
New cards

a patient developed advanced ER +, HER2 - breast cancer and received combo therapy fulvestrant. what cyclin-dependent kinase 4/6 inhibitor is used

a/ palociclib
b/ ibrutinib
c/ imatinib
d/ nilotinib
e/ trastuzumab

a/ palociclib

45
New cards

a patient developed metastatic melanoma and was treated with a single agent. what is the agent

a/ ipilimumab
b/ rituximab
c/ daratumumab
d/ dinutuximab
e/ ofatumumab

a/ ipilimumab

46
New cards

a patient with HER2 amplified trastuzumab refractory breast cancer is looking for an optional therapy. what is best option

a/ lapatinib
b/ imatinib
c/ erlotinib
d/ sorafenib
e/ dasatinib

a/ lapatinib

47
New cards

combo therapy with lenalidomide or bortezmob to treat multiple myeloma and started to experience infusion rxn, peripheral neuropathy, and URT infection. what agent is responsible

a/ daratumumab
b/ elotuzumab
c/ blinatumomab
d/ dinutuximab
e/ venetoclax

a/ daratumumab

48
New cards

a group of patients taking intracellular kinase had 50-70% fatigue, 40-60% developed hypothyroidism, what agent is responsible

a/ sunitinib
b/ ramucirumab
c/ vandetanib
d/ labetalol
e/ nilotinib

a/ sunitinib

49
New cards

a patient developed resistance to a previous treatment for CML and developed thrombosis, hepatotoxicity and pancreatitis. what agent is it

a/ ponatinib
b/ bosutinib
c/ alectinib
d/ idelalisib
e/ everolimus

a/ ponatinib